Cytokines, thyroid diseases and thyroid cancer

Cytokine

Volumn 50, Issue 3, 2010, Pages 229-233

  Lumachi, Franco ^a   Basso, Stefano M M ^a   Orlando, Rocco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Biomarkers; Cytokines; Interleukin; Thyroid cancer; Thyroid diseases; Thyroid tumors

Indexed keywords

ALPHA FETOPROTEIN; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; PARATHYROID HORMONE RELATED PROTEIN; SCATTER FACTOR; SODIUM IODIDE SYMPORTER; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOMATOMEDIN B; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; THYROTROPIN; TRANSCRIPTION FACTOR PAX8; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TROPOMYOSIN; TUMOR MARKER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR;

ASPIRATION BIOPSY; AUTOIMMUNITY; CANCER CELL CULTURE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CYTOKINE PRODUCTION; CYTOLOGY; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THYROID CANCER; THYROID DISEASE; THYROID FUNCTION;

ANIMALS; AUTOIMMUNITY; CYTOKINES; HUMANS; INFLAMMATION; THYROID GLAND; THYROID NEOPLASMS;

EID: 77952546785     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.03.005     Document Type: Review

References (58)

1. Sherman S.I. Thyroid carcinoma. Lancet 2003, 361:501-511.
2. 99m Tc-pertechnetate scintigraphy and fine-needle aspiration cytology in patients with solitary thyroid nodules and thyroid cancer. Anticancer Res 2004, 24:2431-2434.
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics 2006. CA Cancer J Clin 2006, 56:106-130.
4. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
5. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. J Am Med Assoc 2006, 295:2164-2167.
6. Lumachi F., Brunello A., Roma A., Basso U. Medical treatment of malignancy-associated hypercalcemia. Curr Med Chem 2008, 15:415-421.
7. Cooper J.S., Porter K., Mallin K., Hoffman H.T., Weber R.S., Ang K.K., et al. National cancer database report on cancer of the head and neck: 10-year update. Head Neck 2009, 31:748-758.
8. McKay J.D., Lesueur F., Jonard L., Pastore A., Williamson J., Hoffman L., et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001, 69:440-446.
9. Linkov F., Ferris R.L., Yurkovetsky Z., Marrangoni A., Velikokhatnaya L., Gooding W., et al. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin Appl 2008, 10:1575-1585.
10. Lumachi F., Borsato S., Tregnaghi A., Marino F., Koussis H., Brunello A., et al. Frozen-section examination and fine-needle aspiration cytology in patients with solitary thyroid nodules. Eur J Surg Oncol 2008, 4:1007-1008.
11. Brooks A.D., Shaha A.R., DuMornay W., Huvos A.G., Zakowsky H., Brennan M.F., et al. Role of fine-needle aspiration biopsy and frozen section analysis in the surgical management of thyroid tumors. Ann Surg Oncol 2001, 8:92-100.
12. Sapio M.R., Posca D., Raggiali A., Guerra A., Marotta V., Deandrea M., et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol 2007, 66:678-683.
13. Cohen Y., Rosenbaum E., Clark D.P., Zeiger M.A., Umbricht C.B., Tufano R.P., et al. Mutational analysis of BRAF in fine-needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004, 10:2761-2765.
14. Xing M., Clark D., Guan H., Ji M., Dackiw A., Carson K.A., et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 2009, 27:2977-2982.
15. Vesely D., Astl J., Lastuvka P., Matuka P., Sterzl I., Betka J. Serum levels of IGF-I, HGF, TGF beta 1, bFGF and VEGF in thyroid gland tumors. Physiol Res 2004, 53:83-89.
16. Fujarewicz K., Jarzab M., Eszlinger M., Krohn K., Paschke R., Oczko-Wojciechowska M., et al. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocrine Relat Cancer 2007, 14:809-826.
17. Shizuru JA. Autoimmunity and endocrine diseases. Basic and clinical endocrinology 2001, 745-761. Lange Medical Books/McGraw-Hill, New York. F.S. Greenspan, D.G. Gardner (Eds.).
18. Mayer J., Rau B., Gansauge F., Berher H.G. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000, 47:546-552.
19. Ajjan R.A., Watson P.F., Weetman A.P. Cytokines and thyroid function. Adv Neuroimmunol 1996, 6:359-386.
20. Lin D.-J., Chao T.-C., Weng H.-F., Lin K.-D. The roles of cytokines and retinoic acid in regulation of human thyroid cancer cell growth. Cytokine 1998, 10:536-539.
21. Lumachi F., Brunello A., Roma A., Basso U. Cancer-induced hypercalcemia. Anticancer Res 2009, 29:1551-1556.
22. Mundy G.R. Metastasis to bone: causes, consequences and therapeutics opportunities. Nat Rev Cancer 2002, 2:584-593.
23. Lumachi F., Basso S.M.M. Apoptosis: life through planned cellular death. Regulating mechanism, control systems, and relations with thyroid diseases. Thyroid 2002, 12:27-34.
24. Morony S., Warmington K., Adamu S., Asuncion F., Geng Z., Grisanti M., et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia in malignancy. Endocrinology 2005, 146:3235-3243.
25. Stewart A.F. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005, 352:373-379.
26. Bekker P.J., Halloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese Pt, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Min Res 2004, 19:1059-1066.
27. Saito H., Tsunerari T., Onuma E., Sato K., Ogata E., Yamada-Okabe H. Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231. Anticancer Res 2005, 25:3817-3823.
28. Ajjan R.A., Weetman A.P. Cytokines in thyroid autoimmunity. Autoimmunity 2003, 36:351-359.
29. Chang J W.-C., Yeh K.-Y., Shen Y.-C., Hsieh J.-J., Chuang C.-K., Liao S.-K., et al. Production of multiple cytokines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell lines. J Endocrinol 2003, 179:387-394.
30. Miller A., Kraiem Z., Sobel E., Lider O., Lahat N. Modulation of human leukocyte antigen and intracellular adhesion molecule-1 surface expression in malignant and nonmalignant human thyroid cells by cytokines in the context of extracellular matrix. Thyroid 2000, 10:945-959.
31. Ajjan R.A., Watson P.F., Findlay C., Metcalfe R.A., Crisp M., Ludgate M., et al. The sodium-iodine symporter gene and its regulation by cytokines found in autoimmunity. J Endocrinol 1998, 158:351-358.
32. Dohan O., De La Vieja A., Carrasco N. Molecular study of the sodium-iodine symporter (NIS): a new field in thyroidology. Trends Endocrinol Metab 2000, 11:99-105.
33. Zarnegar R. Sodium-iodine symporter and radioactive iodine therapy. Textbook of endocrine surgery 2005, 355-361. Elsevier Saunders, Philadelphia. O.H. Clark, Q.-Y. Duh, E. Kebebew (Eds.).
34. Weetman A.P., Bennett G.L., Wong W.L. Thyroid follicular cells produce interleukin-8. J Clin Endocrinol Metab 1992, 75:328-330.
35. Kuma K., Fukuta S., Sugawara M. Hypothyroidism. Textbook of endocrine surgery 2005, 44-53. Elsevier Saunders, Philadelphia. O.H. Clark, Q.-Y. Duh, E. Kebebew (Eds.).
36. Baur A., Bauer K., Jarry H., Köhrle J. Effects of proinflammatory cytokines on anterior pituitary 5′-deiodinase type I and type II. J Endocrinol 2000, 167:505-515.
37. Davis P.J. Cytokines and growth factors and thyroid hormone. Curr Opin Endocrinol Diabetes Obes 2008, 15:428.
38. Weetman A.P., Tandon N., Morgan B.P. Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells. Lancet 1992, 340(8820):633-636.
39. Blaydes J.P., Wynford-Thomas D. Loss of responsiveness to transforming growth factor beta (TGFbeta) in tightly linked to tumorigeniticy in a model of thyroid tumor progression. Int J Cancer 1996, 65:525-530.
40. Shulte K.M., Jonas C., Krebs R., Röher H.D. Activin A and activin receptors in thyroid cancer. Thyroid 2001, 11:3-14.
41. Kurebayashi J., Tanaka K., Otsuki T., Moruya T., Kunisue H., Uno M., et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 2000, 85:2889-2896.
42. Mineo R., Costantino A., Frasca F., Sciacca L., Russo S., Vigneri R., et al. Activation of hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological affects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology 2004, 145:4355-4365.
43. Nakagawara A. Trk receptor thyrosine kinase: a bridge between cancer and neural development. Cancer Lett 2001, 169:107-114.
44. Wang T., Yu D., Lamb M.L. Trk kinase inhibitors as new treatments for cancer and pain. Exp Opin Ther Pat 2009, 19:305-319.
45. Elisei R., Shiohara M., Koeffler H.P., Fagin J.A. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinomas cell lines and primary thyroid carcinomas. Cancer 1998, 83:2185-2193.
46. Specht M.C., Barden C.M., Fahey T.J. p44/p42-MAP kinase expression in papillary thyroid cancer. Surgery 2001, 130:936-940.
47. Yip I., Peng X.P., Berg L., Hershman J.M. Antitumor actions of interferon-gamma and interleukin-1 beta on human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab 1995, 80:1664-1669.
48. Ohta K., Pang X.P., Berg L., Hershaman J.M. Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab 1996, 81:2607-2612.
49. Khawli L.A., Hu P., Epstein A.L. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Handb Exp Pharmacol 2008, 181:291-328.
50. Linkov F., Lisovich A., Yurkevetsky Z., Marrangono A., Velikokhatnaya L., Nolen B., et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarkers profiling. Cancer Epidemiol Biomarkers Prev 2007, 16:102-107.
51. Schmutzler C., Koehrle J. Innovative strategies for treatment of thyroid cancer. European J Endocrinol 2000, 143:15-24.
52. Zarnegar R., Brunaud L., Kanauchi H., Wong M., Fung M., Ginznger D., et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using trichostatin A, a histone deacetylase inhibitor. Surgery 2001, 132:984-990.
53. - symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86:3430-3435.
54. Schmutzler C., Winzer R., Meissner-Weigl J., Köhrle J. Retinoic acid increases sodium/iodine symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997, 240:832-838.
55. Schmutzler C., Köhrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000, 10:393-406.
56. Handkiewikz-Junac D., Roskosz J., Hasse-Lazar K., Szpak-ulczok S., Puch Z., Kikulska A., et al. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-functional metastatic thyroid cancer: a single-center, 53 patients phase 2 study. Thyroid Res 2009, 2(1):8. 10.1186/1756-6614-2-8.
57. van Herle A.J., Agatep M.L., Padua D.N., Totanes T.L., Canlapan D.V., van Herle H.M., et al. Effects of 13-cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab 1990, 71:755-763.
58. Schreck R., Schnieders F., Schmutzler C., Köhrle J. Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinomas cell lines. J Clin Endocrinol Metab 1994, 79:791-798.